Mathai Mammen, head of R&D for J&J’s Janssen unit (Rob Tannenbaum)
J&J takes a $610M hit as top PhIII prospect goes up in flames after atopic dermatitis study fails
Back in late 2019, Mathai Mammen’s crew stepped off the beaten biotech track to make an unlikely deal, buying out a Phase III ready anti …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
